Last reviewed · How we verify
NCT06954116: CCGLC-017
Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence
Phase 2 trial testing Iparomlimab and Tuvonralimab (QL1706) in Resectable Hepatocellular Carcinoma With High Risk of Recurrence in 26 participants. Not yet recruiting.
31 December 2028
Quick facts
| Lead sponsor | Tongji Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 26 |
| Start date | 1 August 2025 |
| Primary completion | 31 December 2028 |
| Estimated completion | 1 April 2029 |
| Sites | 1 location across China |
Drugs / interventions tested
- Iparomlimab and Tuvonralimab (QL1706) — full drug profile →
- Partial hepatectomy
Conditions studied
- Resectable Hepatocellular Carcinoma With High Risk of Recurrence — all drugs for Resectable Hepatocellular Carcinoma With High Risk of Recurrence →
Sponsor
Tongji Hospital
Who can join
Adults 18 to 75, any sex, with Resectable Hepatocellular Carcinoma With High Risk of Recurrence. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate the impact of iparomlimab and tuvonralimab as preoperative neoadjuvant therapy on recurrence-free survival (RFS), along with its potential improvement in overall survival (OS), in patients with resectable hepatocellular carcinoma (HCC) at high risk of recurrence.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06954116
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Iparomlimab and Tuvonralimab (QL1706)
Trials testing the same drug.
- NCT07502027 — A Clinical Study of Iparomlimab and Tuvonralimab Combined With SOX Following Heterogeneous Radiotherapy as First-line Tr · Phase 4 · not yet recruiting
- NCT07502014 — A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruqui · Phase 2 · not yet recruiting
- NCT07369986 — Immunotherapy for Surgery Avoidance in Vulnerable dMMR Endometrial Cancer · Phase 2 · not yet recruiting
- NCT07315854 — Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric · Phase 2 · recruiting
- NCT07117877 — Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or · Phase 2 · not yet recruiting
Other recruiting trials for Resectable Hepatocellular Carcinoma With High Risk of Recurrence
Currently open trials in the same condition.
- NCT07239245 — Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk R · Phase 2 · recruiting
- NCT07064681 — The Real-world Study of AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING) · recruiting
Other Tongji Hospital trials
Trials by the same sponsor.
- NCT07537946 — Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer · Phase 3 · not yet recruiting
- NCT07537972 — Denosumab Strategy for Liver Cancer With Bone Metastases · Phase 2 · not yet recruiting
- NCT07537959 — Surgery Plus Systemic Therapy for Liver Cancer With Extrahepatic Metastases · NA · not yet recruiting
- NCT07527260 — Effects of Adenoidectomy on Symptoms and IgE Levels in Children With AR · NA · not yet recruiting
- NCT07524712 — Effects of Energy Versus Mechanical Surgical Devices on Postoperative Cough · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06954116 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tongji Hospital
- Last refreshed: 13 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06954116.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing